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Increasing evidence suggests that AR (androgen receptor)
acetylation is critical for prostate cancer cell growth. In the present
study, we identified Pro-B3 (procyanidin B3) as a specific HAT
(histone acetyltransferase) inhibitor. Pro-B3 selectively inhibited
the activity of HATs, but not other epigenetic enzymes. Pro-
B3 substantially inhibited the p300-mediated AR acetylation,
both in vitro and in vivo. Pro-B3 inhibited both p300-dependent
and agonist-induced AR transcription. We demonstrate that
the p300-mediated AR acetylation is critical for the hormone
responsiveness of AR. Interestingly, B3 treatment efficiently
enhanced the antagonist activity of flutamide through suppression
of p300 HAT activity, demonstrating that relative p300 activity
is critical for the antagonist action. Finally, Pro-B3 treatment
inhibited acetylation-dependent prostate cell proliferation and
expression of cell-cycle control genes, subsequently increasing
cell death, indicating the functional importance of AR acetylation
for prostate cancer cell growth.
Key words: acetylation, androgen receptor, histone acetyltrans-
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INTRODUCTION
AR (androgen receptor) plays an important role in normal
male development, as well as prostate cancer cell growth and
progression [1]. AR function is modulated by post-translational
modifications such as acetylation, ubiquitylation, SUMOylation
and phosphorylation [2−5]. p300/CBP [CREB (cAMP-
response-element-binding protein)-binding protein]-mediated
AR acetylation is a key post-translational modification, regula-
ting AR growth control and hormone responsiveness in prostate
cancer cell lines [6]. Tip60 is also known to regulate the
transcription of AR in an androgen-independent manner via
enhancing nuclear translocation of AR [7,8]. There is ample
evidence to suggest that the ligand-induced transcriptional activity
of an acetylation mimetic mutant, ARK630Q, and a somatic mutation
identified in prostate cancer patients at the AR acetylation site,
ARK630T, is greater than that of wild-type AR [2,6,9]. These
AR acetylating-site mimetics also show enhanced responsiveness
at lower DHT (dihydrotestosterone) concentrations than wild-
type AR [6]. In addition, the DHT antagonist flutamide
antagonizes DHT-induced wild-type AR activity; however, the
AR acetylation mimetics are relatively resistant, suggesting that
AR acetylation might be an ideal target for novel tumour therapies
[6,7,9].
As suggested in previous studies, the development of
HATi [HAT (histone acetyltransferase) inhibitors] from dietary
compounds, such as garcinol, curcumin, anacardic acid and
EGCG (epigallocatechin-3-gallate), are current therapeutic goals
[10−13]. Garcinol inhibits p300 and PCAF (p300/CBP-activating
factor) in vitro and in vivo [10], both anacardic acid and EGCG
inhibit Tip60, as well as p300 and PCAF [12,13], and curcumin
inhibits p300 and PCAF [11]. Therefore p300 is the common
target of these HATi. Since either mutation or amplification of
p300 has been reported in colorectal, breast and prostate cancer,
the dysregulation of protein acetylation by p300 is presumably
associated with oncogenesis [14,15]. Even though the antitumour
activities of these HATi are well documented, it is still unclear
whether HATi-mediated inhibition of p300 activity is correlated
with cancer cell proliferation.
During the effort to identify natural anti-HAT substances, we
found that procyanidins from grape seed extracts possess a potent
anti-HAT activity. Grape seed is a rich source of procyanidins,
polymer chains of flavonoids such as catechins [16]. Grape seed
procyanidins are known to possess both chemopreventative and
antiproliferative effects on breast, prostate, skin and colorectal
cancer cells [17−20]. Although procyanidin is known to inhibit
the growth of prostate cancer cells, it is unclear how procyanidin
suppresses prostate cancer cell survival. In the present study, we
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demonstrate that Pro-B3 (procyanidin B3) exhibits the strongest
inhibition against p300 HAT of all catechin derivatives. We show
that Pro-B3 suppresses the androgen-dependent transcription
of AR. Furthermore, we show that Pro-B3 suppresses p300-
enhanced AR transcription in an acetylation-dependent manner.
Finally, we demonstrate the enhanced antagonistic activity
of Pro-B3, which may aid in the development of effective
chemopreventive therapeutics.
EXPERIMENTAL
Cell culture, reagents and plasmids
Human LNCap and PC-3 cells were maintained in RPMI 1640
(Gibco/BRL) supplemented with 10% FBS (fetal bovine serum;
Hyclone). Cells grown in six-well plates were supplemented
with fresh medium 2 h before transfection with 1.5 μg of
DNA, according to the manufacturer’s protocol for Effectin
transfection (Qiagen). After 2−3 h of incubation, cells were
treated with medium supplemented with charcoal-dextran-
treated FBS, containing either 1 nM synthetic androgen R1881
(NEN/Life Sciences Products) or 1 μM antagonist, including
flutamide. Cell lysates were prepared for luciferase assays,
according to the manufacturer’s instructions (Promega). The
results were obtained from at least three sets of transfections
and presented as mean values. For the siRNA (small
interference RNA) experiments, both PC-3 and LNCaP cells
were seeded the night before transfection such that cells reached
30−40% confluence by the time of transfection. The siRNAs
for p300 were chemically synthesized by GenePharm. The
siRNA sequence is as follows: p300, 5′-A2218AUGCUACUUC-
UCGAGGAAACA2238-3′. Procyanidin B1 and B2 were purchased
from Sigma−Aldrich. Pro-B3 was chemically synthesized by
Dr Younghwa Na (Catholic University of Daegu, Gyeongbuk,
Korea). Antibodies against acetylated H3 and p300 were
purchased from Upstate Biotechnology, and AR and acetylated
lysine residues were from Santa Cruz Biotechnology. The
AR−GFP (green fluorescent protein) plasmid [GFP−AR (wt)],
expressing C-terminally GFP-tagged AR protein, was provided
by Dr Toshihiko Yanase (Fukuoka University, Fukuoka, Japan).
Both the non-acetylation-mimetic mutant AR−GFP plasmid
[GFP−AR (K630/632/633R)] and the acetylation-mimetic
mutant AR−GFP plasmid [GFP−AR (K630/632/633Q)] were
provided by Dr Masaki Shiota, Dr Akira Yokomizo and Dr Seiji
Naito (Kyushu University, Fukuoka, Japan). The plasmids for
reporter gene assays [PGL-PSA (ARE)−Luc and FLAG−AR;
ARE is androgen-response element, PSA is prostate-specific
antigen] have been described previously [21]. The recombinant
p300 HAT domain for the in vitro acetylation assay was
purchased from Upstate Biotechnology. For the GST (glutathione
transferase)-fusion protein, AR [aa (amino acids) 507−645] was
subcloned into the pGEX4T-1 GST-expression vector (Amersham
Pharmacia Biotech). The construct for GST−AR (aa 507−645)
was expressed in Escherichia coli BL21 cells and affinity-purified
using glutathione−Sepharose 4B beads (Amersham Pharmacia
Biotech) following the manufacturer’s protocol. GST−histone
H4 has been described previously [12].
Clinical specimens
All patient-derived specimens were collected and archived under
protocols approved by the IRBs (Institutional Review Boards) of
Yonsei University College of Medicine (Seoul, South Korea).
Archival tissues in paraffin blocks were retrieved from the
Department of Pathology at Yongdong Severance Hospital,
Yonsei University College of Medicine. Specimens were stained
with antibodies specific for p300 (Santa Cruz Biotechnology).
HAT, HDAC (histone deacetylase) and HMT (histone
methyltransferase) assays
HeLa cell NE (nuclear extract) was prepared as described
previously [22]. HAT activity and HDAC activity assays were
performed using NEs following the manufacturer’s protocol
(Biovision Biotechnology). For HAT activity assays, IPs
(immunoprecipitations) were performed in HeLa NEs using anti-
p300, anti-Tip60, anti-CBP and anti-PCAF antibodies (Santa Cruz
Biotechnology). Pre-cleared NE was incubated with antibodies
overnight with Protein A/G PLUS agarose beads at 4 ◦C. IPs
were collected and washed with HAT assay buffer [50 mM
Tris/HCl (pH 8.0), 10% glycerol and 0.1 mM EDTA]. For
recombinant p300 HAT activity assays, HAT activity assays were
performed using active p300 (Upstate Biotechnology) following
the manufacturer’s protocol (Biovision Biotechnology). All
samples were counted with a multi-purpose scintillation counter
(LS 6500; Beckman). For Figure 2(A), active p300 was incubated
with HAT assay buffer {50 mM Hepes (pH 8.0), 10% glycerol,
1 mM DTT (dithiothreitol), 1 mM PMSF, 10 mM sodium butyrate
and 1 μl of [3H]acetyl-CoA}, 1 μg of GST−H4 recombinant
protein and increasing amounts of Pro-B3 at 30 ◦C for 1 h.
Samples were separated by SDS/PAGE (15% gels) and analysed
by autoradiography. For HMT activity assays, assay buffer and
core histones were from the HMT Assay Reagent kit (Upstate
Biotechnology). HMT activity assays were performed following
the manufacturer’s protocol. Core histones were incubated in
MTase (methyltransferase) buffer [final concentrations 50 mM
Tris/HCl (pH 8.0), 1 mM PMSF and 0.5 mM DTT], 1 μl
(0.55 μCi) of [3H]AdoMet (S-adenosyl-L-[methyl-3H] methion-
ine; Amersham Pharmacia Biotech), and 1 μg of HeLa NE for 1 h
at 30 ◦C in a total volume of 20 μl. The reaction was spotted on
to P-81 paper (Upstate Biotechnology) for scintillation counting.
P-81 paper was washed three times with 10% trichloroacetic acid
for 15 min. P-81 papers were then washed with 95% ethanol for
5 min at room temperature (20 ◦C) and allowed to dry. Dry P-81
papers were counted with a multi-purpose LS 6500 scintillation
counter (Beckman).
RT (real-time) PCR analysis and ChIP (chromatin IP) assays
RNA extraction, RT-PCR and ChIP were performed as described
previously [21]. The RT-PCR analysis and quantification
were performed with SYBR Green PCR Master Mix
reagents on an ABI Prism 7300 Sequence Detection
System. The singularity and specificity of amplification
were verified by dissociation analysis software. All samples
were normalized to human GAPDH (glyceraldehyde-3-
phosphate dehydrogenase). Primer sequences for amplification of
NKX3-1 RNA were forward, 5′-CTGTCAGCCCCTGAACGG-
3′ and reverse, 5′-AACCATATCTTCACTTGGGTCTCC-3′.
Primer sequences for amplification of the PSA RNA were
forward, 5′-AGTCTGAGGAGGTGTTCTGGTG-3′ and reverse,
5′-GAGGTCGTGGCTGGAGTCATCA-3′. All reactions were
performed in triplicate. Relative expression levels and S.D.s were
calculated using the comparative method.
For ChIP assays, LNCaP cells were first transfected with
the GFP−AR plasmids indicated and chromatin was isolated
as described previously [21]. The antibody against GFP was
purchased from Santa Cruz Biotechnology, and histone H3
and acetylated histone H3 antibodies were purchased from
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Figure 1 Pro-B3 has specific anti-HAT activity
(A) Chemical structures of catechin derivatives. (B) Pro-B3 has potent anti-HAT activity toward catechin derivatives. HAT activity was assayed with a colorimetric assay kit. HeLa cell NE provided the
source of HAT enzymes. Values are means +− S.D. for three independent experiments. (C) Pro-B3 inhibits HAT activity in a dose-dependent manner. HAT activity colorimetric assays were performed
with indicated concentrations of B3. (D) Pro-B3 treatment had no effect on either HDAC or HMT activity. HDAC activity was assayed with an HDAC activity colorimetric assay kit. TSA (trichostatin A)
was used as a control inhibitor for HDAC activity. Values are means +− S.D. for three independent experiments. HMT assays were performed in 30 μl reaction mixtures in the presence or absence of
Pro-B3, using HeLa cell NEs as the source of enzyme, and then processed for filter-binding assays.
Upstate Biotechnology. Primers used for ChIP analysis for
PSA were 5′-CATGTTCACATTAGTACACCTTGCC-3′ and 5′-
TCTCAGATCCAGGCTTGCTTACTGRC-3′.
IP and Western blot analysis
Cell extracts were prepared using lysis buffer [1% Nonidet
P40, 1% soduim deoxycholate, 0.1% SDS, 0.15 M and 50 nM
Tris/HCl (pH 7.4), incubated with the antibodies indicated
and then incubated with 20 μl of Protein A/G agarose
overnight at 4 ◦C. Co-immunoprecipitated proteins were separated
by SDS/PAGE (10% gels), transferred on to nitrocellulose
membranes, subjected to immunoblot analysis and visualized by
autoradiography.
Colony formation and MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl-2H-tetrazolium bromide] assay
The degree of cell proliferation was evaluated by MTT assays.
In brief, 10 μl of MTT solution (5 mg/ml) was added to each
well 4 h prior to the end of the incubation. Formazan crystals
formed in the cells were dissolved by adding 100 μl of MTT
solvent (0.01 M HCl in 10% SDS). The absorbance at 550 nm
was measured using a spectrophotometer 24 h after the addition
of the MTT solvent. Colony-formation assays were performed
using the CytoSelectTM 96-well Cell Transformation Assay kit
(Cell Biolabs), according to the manufacturer’s instructions.
Annexin V staining and FACS analysis
Cells were stained with both Annexin V−FITC and propidium
iodide, using the ApoScan Annexin-V FITC Apoptosis Detection
Kit (BioBud), according to the manufacturer’s protocol.
Alternatively, we fixed cells in 70% (v/v) ethanol and stained
them with a solution containing RNase A (50 μg/ml) and
propidium iodide (50 μg/ml).
Statistical analysis
Statistical analysis was performed using a Student’s t test with the
SPSS program. P < 0.05 was considered to be significant.
RESULTS
Pro-B3, a novel HATi, exhibits the highest anti-HAT activity of all
catechin derivatives
During an ongoing screen of natural compounds for anti-HAT
activity, we found that a methanol extract of grape seeds has
potent anti-HAT activity against the HAT p300/CBP [16]. The
most abundant polyphenols in grape seeds are procyanidins,
which are also found in cereals, fruits and tea. As shown in
Figure 1(A), the procyanidin is composed of catechin dimers.
Since catechin derivatives possess anti-HAT activity [12,23],
we next compared the anti-HAT activity of Pro-B3 to the
activities of other catechin derivatives. As shown Figure 1(B),
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Figure 2 Pro-B3 inhibits p300-dependent AR acetylation in vitro and in vivo
(A) Pro-B3 inhibits p300 HAT activity in a dose-dependent manner in vitro. In vitro HAT activity assays were performed with GST−H4 tail and p300 HAT enzymes in the presence or absence of
Pro-B3, and subsequently processed for fluorography. (B) HAT activity colorimetric assays were performed with immunoprecipitated HAT proteins, as indicated. The results are shown as the per-
centage of non-treated Pro-B3. (C) Pro-B3 inhibits the p300-mediated AR acetylation in vitro. In vitro acetylation assays were performed with GST–AR (aa 507−645) in the presence or absence
of B3, and subsequently processed for Western blot analysis with an antibody against acetylated lysine. (D) Pro-B3 treatment prevented the ligand-dependent AR acetylation in vivo. To assess the
levels of endogenous AR acetylation, LNCaP cells were treated with R1881 and/or Pro-B3. The immunoprecipitated proteins were processed for Western blot analysis with the antibodies indicated
(top panel). (E) To assess the levels of exogeneous AR acetylation, PC-3 cells were transfected with either wild-type GFP−AR or acetylation mutant GFA−AR (K630R/632R/633R) with R1881 and/or
Pro-B3. The levels of AR acetylation were assayed by Western blot analysis with the antibodies indicated. Ac-Lys, acetylated lysine; IP, immunoprecipitation; WB, Western blot.
EGCG exhibited HAT inhibitory activities by up to 60% at
50 μM, consistent with a previous study [12]. Pro-B3 inhibited
90% of HAT activity in a dose-dependent manner (Figure 1C),
and exhibited the highest anti-HAT activity of the procyanidin
derivatives, although procyanidin B1 and B2 had levels of anti-
HAT activity similar to EGCG (Figure 1B). To examine enzyme
specificity, we first tested the effect of Pro-B3 on HDAC and
HMT activities. When HeLa NEs were used as a source of HDAC
enzymes, deacetylation activity was not affected by the presence
of Pro-B3 (Figure 1D). This suggests that Pro-B3 is not a specific
inhibitor of HDACs.
Pro-B3 inhibits p300-dependent AR acetylation
To examine whether Pro-B3 is a general HATi or a specific HATi,
HAT activity was measured for immunoprecipitated p300, Tip60,
PCAF and CBP enzymes. As shown in Figure 2(A), Pro-B3
was found to be an efficient inhibitor of p300 acetyltransferase
activity, exhibiting 60% inhibition compared with the control.
Under similar conditions, Pro-B3 only inhibited Tip60, PCAF
and CBP acetyltransferase activities by 40%, 23% and 20%
respectively. These results suggest that Pro-B3 preferentially
inhibits p300 HAT activity. To further validate the B3-mediated
selective inhibition of HAT activity of p300, we next analysed
radiolabelled GST−H4 protein by SDS/PAGE and fluorography.
As shown in Figure 2(B), Pro-B3 strongly quenched p300 HAT
activity in a dose-dependent manner, consistent with the results
of the HAT activity colorimetric assays. We next examined how
Pro-B3 inhibited p300 HAT activities. For this experiment, we
studied the kinetics of p300 HAT activity in the presence of Pro-
B3 in reactions with changing histone concentrations. We found
that Km and Vmax were decreased with Pro-B3, demonstrating
that Pro-B3 does not bind to the active sites of p300, but to
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some other site on the enzyme (see Supplementary Figure S1
at http://www.BiochemJ.org/bj/433/bj4330235add.htm). These
results establish that Pro-B3 uncompetitively inhibits the p300
HAT activity, but not other epigenetic enzymes.
Since AR is acetylated by p300, we next examined whether
Pro-B3 directly inhibits p300-mediated AR acetylation. In vitro
acetylation assays were performed in the presence or absence
of Pro-B3, using recombinant GST−AR (aa 507−645) as a
substrate. As shown in Figure 2(C), the acetylation of GST−AR
was detected in the presence of active p300 protein, but not
without p300 protein. Upon Pro-B3 treatment, the p300-induced
acetylation was reduced, indicating that Pro-B3 suppresses
the acetylation of AR in vitro. To confirm the inhibition of
p300-mediated AR acetylation by Pro-B3, we assessed the
effect of Pro-B3 treatment on androgen R1881-induced acetyl-
ation of AR in LNCaP prostate cancer cells. To do this, IP was
performed on LNCaP cell lysates with a specific AR antibody
and Western blot analysis was used to determine the amount of
acetylation at specific lysine residues. As shown in Figure 2(D),
AR acetylation was increased in LNCaP cells in the presence of
R1881, and the levels of AR acetylation was reversed by Pro-
B3 treatment, indicating that Pro-B3 suppresses the acetylation
of AR in vivo. The lysine residues (Lys630/Lys632/Lys633) of AR
within the hinge region are known to be acetylated by p300.
We next examined whether androgen-induced AR acetylation is
inhibited by Pro-B3 via these lysine residues of AR. For this
experiment, PC-3 cells were transfected with GFP−AR (wt) or
the non-acetylation mimetic mutant GFP−AR (K630/632/633R)
expression plasmids, and the levels of AR acetylation were
assessed by Western blot analysis. Androgen efficiently induced
the acetylation of GFP−AR (wt), whereas Pro-B3 treatment
inhibited the R1881-induced acetylation of AR. On the other
hand, neither R1881 nor Pro-B3 treatment had an effect on
the acetylation level of GFP−AR (K630/632/633R), indicating
that the inhibition of R1881-induced AR acetylation by Pro-B3
treatment is mainly through the lysine residues in the hinge region
of AR (Figure 2E). Collectively, these data suggest that Pro-B3
inhibits p300-mediated AR acetylation both in vitro and in vivo.
Pro-B3 suppresses R1881-mediated AR transcription in a
p300-dependent manner
To measure the effects of Pro-B3 on AR-mediated transcription
in LNCaP cells, we used an androgen-dependent reporter vector
(pGL3-PSA) containing the ARE and the luciferase reporter
gene. LNCaP cells were treated with the synthetic androgen
R1881 in the presence or absence of Pro-B3 for 48 h in RPMI
1640 medium containing charcoal-stripped FBS. As shown in
Figure 3(A) (left-hand panel), Pro-B3 inhibited agonist-bound
AR-mediated transcription, in a dose-dependent manner.
We next performed RT-PCR analysis to determine whether Pro-
B3 inhibits R1881-induced transcription of AR-regulated genes.
LNCaP cells were exposed to 0, 50 or 100 μM Pro-B3 for 18 h,
and total RNA samples were isolated. Consistent with the results
of the reporter assay, both an androgen-dependent increase and
Pro-B3-induced reduction were observed in the mRNA levels of
PSA and NKX 3.1 (Figure 3A, right-hand panel). Taken together,
these studies indicate that Pro-B3 inhibits the agonist-induced
AR-dependent transcription.
Since several HATi from natural substances have already been
identified, we compared the relative efficacy of Pro-B3 with the
other known HATi. As shown in Figure 3(B), Pro-B3 was the
most potent inhibitor of agonist-induced AR transcription among
the reported HATi, although the anti-HAT activity of curcumin
was similar to that of Pro-B1. Therefore the tendency of AR-
mediated inhibition by HATi seems to be closely related to their
HAT activities.
p300 plays a role in androgen-dependent AR transcription. Thus
we next asked whether Pro-B3 suppresses androgen-dependent
AR transcription via inhibition of p300 activity. As shown in
Figure 3(C), siRNA specific for p300 was able to efficiently reduce
the level of p300 when used at a concentration of 1 nM. Similar to
Pro-B3 treatment, the depletion of p300 dramatically relieved
androgen-dependent AR transcription. Interestingly, combined
treatment of Pro-B3 with siRNA against p300 further reduced
the transcription of AR-target genes, indicating that Pro-B3
suppresses AR transcription via inhibition of p300 activity
(Figure 3D).
Pro-B3 inhibits p300-enhanced hormone responsiveness
and enhances the antagonist action
Since p300 plays a role in the hormone responsiveness of
AR, we next examined whether Pro-B3 inhibits the hormone
responsiveness of AR in an acetylation-dependent manner.
For this experiment, either GFP−AR (wt) or GFP−AR
(K630/632/633R) with pGL3-PSA reporter plasmid and pSG5-
p300 plasmid was transiently transfected into PC-3 cells.
The p300 further enhanced the GFP−AR (wt)-mediated
transcription in the presence of ligand, which was abrogated
by Pro-B3 treatment. Interestingly, neither the overexpression
of p300 nor Pro-B3 treatment had a significant effect on
GFP−AR (K630/632/633R)-dependent transcription, suggesting
that p300-mediated AR acetylation is critical for the hormone
responsiveness of AR (Figure 4A and Supplementary Figure S2A
at http://www.BiochemJ.org/bj/433/bj4330235add.htm).
Given the knowledge that the HATi Pro-B3 inhibits the p300-
enhanced hormone responsiveness of AR, we next tested the
possibility that Pro-B3 enhances antagonist action. As shown in
Figure 4(B), overexpression of p300 in LNCaP cells resulted in
a substantial increase in the transcription of PSA with R1881
treatment, compared with LNCaP cells with R1881 alone. As
expected, flutamide treatment efficiently suppressed the R1881-
induced transcription of the PSA gene. Importantly, Pro-B3
treatment (50 μM) repressed transcription of both the NKX3.1
and PSA genes to a level similar to flutamide treatment. More
importantly, co-treatment of Pro-B3 with flutamide increased
the inhibition of p300-mediated AR transcription, suggesting
that Pro-B3 enhances the antagonistic activity of flutamide via
suppression of p300 activity (Figure 4B).
The enhancement of antagonistic action by Pro-B3 led us
to ask whether the relative level of p300 is critical for
the inhibition of AR-mediated transcription by Pro-B3 and
hormone responsiveness of AR. As shown in Figure 4(C)
and Supplementary Figure S2(B), knock down of p300
further potentiated the suppression of GFP−AR (wt)-mediated
transcription, but not in the case of mutant GFP−AR
(K630/632/633R). Furthermore, combined treatments of si-p300
with either flutamide or Pro-B3 efficiently inhibited GFP−AR
(wt)-mediated transcription, compared with si-p300 alone. As
expected, GFP−AR (K630/632/633R)-mediated transcription
was not affected upon silencing of p300. These data suggest that
the overall level of p300 is a key determinant of antagonist activity.
We next asked whether p300 mediates the acetylation of AR,
as well as the histone hyperacetylation, which is required for AR-
mediated transcriptional activation, and subsequently leads to the
up-regulation of PSA transcription. For this experiment, either
GFP−AR (wt) or GFP−AR (K630/632/633R) was transfected
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Figure 3 Pro-B3 suppresses R1881-mediated AR transcription in a p300-dependent manner
(A) Pro-B3 inhibited R1881-induced AR-dependent promoter activity in LNCaP cells. LNCaP cells were transfected with an AR-binding site-driven luciferase reporter plasmid [PGL-PSA (ARE)−Luc]
and treated with R1881 and/or increasing amounts of Pro-B3. Whole-cell extracts were used in luciferase assays. Results are presented as the means of two independent experiments performed in
triplicate (left-hand panel). Total RNA was prepared from each sample and used for quantitative RT-PCR to measure the expression of the AR target genes, PSA and NKX3.1. As controls, the level of
GAPDH mRNA was also measured by quantitative RT-PCR in the same batch of RNA samples. The levels of transcription were shown as the fold-induction compared with the level of transcription
in the absence of R1881, which was set as 1 (right-hand panel). *P < 0.01 compared with R1881; #P < 0.05 compared with R1881. (B) Pro-B3 is the strongest inhibitor of R1881-dependent AR
transcription of the known HAT inhibitors. LNCaP cells were treated with 50 μM HAT inhibitors and the effect on transcriptional activation of PSA was analysed by quantitative RT-PCR analysis.
Values are the means +− S.D. for at least three independent experiments. *P < 0.01 for Pro-B3 compared with curcumin. (C) Knockdown of p300 with specific siRNA. LNCaP cells were transfected
with control (scrambled) siRNA or siRNAs against p300 at the concentrations indicated. At 3 days after treatment, whole-cell extracts were prepared and the level of p300 was determined by Western
blot analysis with the p300 antibody. Western blot results for PCAF and tubulin served as specificity controls. (D) Pro-B3 suppresses the AR transcription via inhibition of p300 activity. LNCaP cells
were first treated with siRNA against p300. The cells were then treated with 1 nM R1881 and/or 50 μM B3 for 12 h and the level of transcription of NKX3.1 and PSA was analysed by quantitative
RT-PCR analysis. Values are means +− S.D. for at least three independent experiments. *P < 0.01 for Pro-B3+si-p300 compared with si-p300.
into LNCaP cells in the presence or absence of si-p300 or
Pro-B3, and then ChIP assays were performed using anti-GFP,
p300, acetylated histone H3 or histone H3 antibodies. To more
precisely measure the recruitment of AR and p300, we used RT-
PCR analysis. The results in Figure 4(D) showed that R1881
treatment led to a significant increase in the binding of GFP−AR
(wt) to the enhancer region of PSA. Although Pro-B3 or si-p300
treatment had little effect on the recruitment of GFP−AR (wt), the
recruitment of p300 was reduced by treatment with si-p300 or Pro-
B3. Consequently, the level of histone H3 acetylation was greatly
increased by R1881 and, conversely, Pro-B3 treatment reversed
the R1881-induced histone H3 hyperacetylation. Importantly,
neither Pro-B3 nor si-p300 treatment had an effect on the
recruitment of either p300 or histone acetylation in the presence
of GFP−AR (K630/632/633R), suggesting that p300-mediated
AR acetylation is required for the AR-mediated transcriptional
activation.
Pro-B3 specifically inhibits acetylation-dependent prostate cancer
cell growth
Since AR acetylation is closely correlated with prostate cancer cell
growth, we next examined the effect of Pro-B3 on this function
of AR. To do this, we performed MTT assays in LNCaP, HEK
(human embryonic kidney)-293 and NIH 3T3 cell lines. As shown
in Figure 5(A), Pro-B3 treatment increased LNCaP cell death by
approx. 95% at 100 μM, but did not affect either NIH 3T3 or
HEK-293 cells. This indicated that B3 treatment reduces cell
viability rather than causing cytotoxicity.
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Figure 4 Pro-B3 inhibits p300-enhanced hormone responsiveness and enhances antagonist action
(A) Pro-B3 suppressed the hormone responsiveness of AR via inhibition of p300-mediated AR acetylation. PC-3 cells were transfected with the indicated AR−GFP expression plasmids and PGL-PSA
(ARE)−Luc reporter plasmid. The cells were then treated with 1 nM R1881 and/or Pro-B3 (50 μM) for 12 h. Whole-cell extracts were used in luciferase assays. Results are presented as the means
of two independent experiments performed in triplicate. KR, K630/632/633R. (B) Pro-B3 enhanced the antagonist activity of flutamide via suppression of p300 activity. LNCaP cells were first
transfected with either p300 expression plasmid or control psg5.1 control vector. The cells were then treated with R1881 (1 nM), flutamide (10 μM) or B3 (50 μM), individually or in combination,
for 12 h and the levels of transcription from PSA and NKX3.1 were analysed by quantitative RT-PCR analysis. Values are means +− S.D. for at least three independent experiments. *P < 0.01 for
flutamide+Pro-B3 compared with flutamide; #P < 0.01 for flutamide + Pro-B3 compared with flutamide. (C) The relative level of p300 is critical for the inhibition of AR-mediated transcription
by B3 and hormone responsiveness of AR. PC-3 cells were transfected with the indicated AR−GFP expression plasmids and PGL-PSA (ARE)−Luc reporter plasmid. The cells were then treated
with R1881 (1 nM), flutamide (10 μM) or Pro-B3 (50 μM), individually or in combination, for 12 h. Whole-cell extracts were used in luciferase assays. Results are presented as the means of two
independent experiments performed in triplicate. **P < 0.05 compared with si-p300. (D) Pro-B3 inhibits the p300-dependent acetylation of both AR and histone tails, and subsequent chromatin
targeting of p300. LNCaP cells were transfected with indicated AR−GFP expression plasmids with or without si-p300. The cells were then treated with 1 nM R1881 and/or Pro-B3 (50 μM) for 12 h,
and the recruitment of GFP−AR proteins and p300 to the enhancer region of the PSA gene was then determined by ChIP assays using antibodies, as indicated. The results were analysed by RT-PCR
and are shown as the percentage of input. *P < 0.01 for +R1881 or +R1881+Pro-B3 compared with − R1881; #P < 0.05 for +R1881+si-p300 compared with − R1881.
To further examine the role of AR acetylation on prostate
cancer cell proliferation, PC-3 cells were transfected with
either GFP−AR (wt) or acetylation-mimicking GFP−AR
(K630/632/633Q) and/or Pro-B3 in the absence of R1881, and the
relative rate of cell proliferation was assessed by colony-formation
assays. The overexpression of acetylation-mimicking GFP−AR
(K630/632/633Q) enhanced cell proliferation compared with
GFP-AR (wt). Pro-B3 treatment failed to suppress the
increase of cell proliferation by GFP−AR (K630/632/633Q),
whereas it efficiently blocked wild-type AR−GFP-enhanced cell
proliferation (Figure 5B). These data indicate that Pro-B3 inhibits
prostate cancer cell proliferation by blocking AR acetylation.
Next, we examined the effect of Pro-B3 on cell proliferation
by assessing the expression of growth control genes. Western
blot analysis of LNCaP cell lysates demonstrated that cyclin
D1 and cyclin E protein levels were both decreased by
Pro-B3 treatment. In addition, si-p300 treatment blocked
the R1881-induced expression of both genes. These results
suggest that the enhanced growth advantage correlated with
increased activation of cell-cycle control genes is regulated by
AR acetylation (Figure 5C and Supplementary Figure S3 at
http://www.BiochemJ.org/bj/433/bj4330235add.htm).
As AR acetylation mimetic mutants are shown to be resistant
to apoptosis [9], we next examined the effect of Pro-B3 on
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Figure 5 Pro-B3 specifically inhibits the acetylation-dependent prostate cancer cell growth
(A) Pro-B3 inhibits the prostate cancer cell viability and proliferation by blocking AR acetylation. Pro-B3 treatment efficiently decreased viability of LNCaP cells. LNCaP, PC-3, HEK-293 and NIH
3T3 cells were treated with serum-free medium containing increasing amounts of Pro-B3, for 72 h. Cell viability was determined by MTT assays, as described in the Materials and methods section.
Values are means +− S.D. for three independent experiments (top panel). *P < 0.01; #P < 0.001 compared with without B3. (B) The anti-proliferative effects of Pro-B3 on LNCaP cells. LNCaP
cells were transfected with either wild-type (wt) AR−GFP or mutant (mt) AR−GFP and/or 50 μM Pro-B3 and seeded in soft agar. Colony numbers and sizes (percentage of colonies with >100
cells) are shown at day 4 (bottom panel). *P < 0.01; #P < 0.001 for wild-type AR−GFP+Pro-B3 compared with wild-type AR−GFP. (C) Pro-B3 inhibits the expression of cell-cycle control genes.
LNCaP cells were treated with either 50 μM Pro-B3 or si-p300 in the presence or absence of R1881. The cell lysates were analysed by Western blot using antibodies, as indicated. (D) HATi Pro-B3
efficiently promotes cellular apoptotic responses. PC-3 cells were transfected with GFP−AR (wild-type) or GFP−AR (KQ) in the presence or absence of Pro-B3. After transfection for 48 h, cells
were stained with FITC-conjugated Annexin V. The positive cells were measured by flow cytometry. Values are the means +− S.D. for three independent experiments. KQ, K630/632/633Q. (E) p300 is
highly expressed in high Gleason grade prostate cancers (PCa). Specimens of Gleason grade 3, 6 and 9 PCa were stained for p300. The data are representative of three separate specimens for each
classification. IHC, immunohistochemistry; WB, Western blot.
apoptosis in prostate cancer cells using the ApoDETECT Annexin
V-FITC Kit, which detects early stages of apoptosis. Apoptotic
cells can be recognized and distinguished from necrotic cells
using flow cytometry after double staining by Annexin V-FITC
and propidium iodide. As shown in Figure 5(D), combinatorial
treatment of Pro-B3 with flutamide induced significant apoptosis
in GFP−AR (wt)-transfected PC-3 cells, compared with
flutamide alone. However, flutamide treatment with Pro-B3
did not show a synergistic effect on apoptosis in GFP−AR
(K630/632/633Q)-transfected PC-3 cells (Supplementary Fig-
ure S4 at http://www.BiochemJ.org/bj/433/bj4330235add.htm).
These results suggest that the HATi Pro-B3 inhibits
AR acetylation-dependent prostate cancer cell growth and
synergistically promotes cellular apoptotic responses with
flutamide in prostate cancer cells.
Since our data consistently showed the critical roles of p300
on AR acetylation-dependent prostate cancer cell growth, we
next sought to investigate the pathological relevance of p300
in prostate cancer development. To this end, we examined the
level of p300 expression in Korean prostate cancer tissues by
immunohistochemsitry. As shown in Figure 5(E), the expression
of p300 was significantly higher in high-grade tumours with
Gleason grade 9 compared with low-grade tumours with Gleason
grades 3 and 5, confirming a previous report [14]. These
data demonstrated the pathological relevance of p300 in the
progression of prostate cancer.
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DISCUSSION
In the present study, we have shown for the first time that
procyanidins possess inhibitory activities against HAT, and that
Pro-B3 possesses the highest anti-HAT activity among the
catechin derivatives. Pro-B3 is a catechin dimer found in barley
and beer. During a screen for HATi from natural substances, we
found that grape seed extract exhibits high anti-HAT activity.
Grape seed extract also exhibits strong antitumour activity and
contains high levels of phenolic derivatives, especially dimers,
trimers and oligomers of catechin, epicatechin and gallate. Among
them, Pro-B3 had the highest anti-HAT activity, especially against
p300 HAT activity. Interestingly, the inhibitor activity of Pro-B3
is approx. 2-fold higher than both B1 and B2, suggesting that the
position of the catechin monomer is a key factor for anti-HAT
activity. The anti-HAT activity of catechin derivatives is likely
to be attributed to the structural feature of catechin, since we
failed to detect anti-HAT activity from other flavonoid derivatives,
including Sophoretin, Quercetin and Meletin (results not shown).
Thus the anti-cancer or cancer-preventive effects of catechin
derivatives in grape seed may correlate with anti-HAT activity.
In addition to histones, more than 70 non-histone proteins
are reversibly acetylated by HAT in relation to apoptosis,
inflammation, cell-cycle factors, co-activators and structural
proteins [24]. This acetylation modulates multiple cellular events,
including protein stability, nuclear translocation, protein−protein
interaction and cell growth. The nuclear hormone receptor AR
is also acetylated by p300, PCAF and Tip60, and acetyl-
ation of AR regulates co-regulator recruitment and growth proper-
ties of the receptor in cultured cells and in vivo. Previous studies
have shown that the overexpression of AR acetylation mimetic
mutants leads to reduced apoptosis and an enhanced growth
rate with the increased transcription of cell-cycle-regulated genes
[9]. Furthermore, point mutations of lysine residues within the
acetylation motif of AR have been identified in prostate cancer
tissues. This collectively suggests that AR acetylation is a
promising target for the development of more effective antagonists
of prostate cancer. In vivo acetylation assays have demonstrated
that the R1881-induced acetylation of AR is efficiently suppressed
by Pro-B3 treatment. Interestingly, Pro-B3 treatment inhibited
p300-dependent wild-type AR−GFP transcription, but not that
of an acetylation mutant of AR−GFP, suggesting that p300-
mediated AR acetylation is crucial for AR transcriptional
activation. Tip60-mediated AR acetylation is a critical event for
AR translocation [7,8]. In addition, Pro-B3 also inhibited the
HAT activity of Tip60, although less than that of p300. However,
we failed to detect a change of ligand-dependent translocation
of AR upon Pro-B3 treatment (Supplementary Figure S5 at
http://www.BiochemJ.org/bj/433/bj4330235add.htm), indicating
that the inhibitory effect of Pro-B3 on the AR function is not
related to the Tip60-dependent pathway. p300 acetylates the
lysine residue at 630 of AR and regulates coactivator−corepressor
complex binding, altering expression of growth control genes to
promote aberrant cellular growth in vivo [25]. On the other hand,
the alteration of the lysine residue at 630 of AR does not
affect the distribution of AR, indicating p300-mediated AR acetyl-
ation is not correlated with subcellular localization of AR [9].
Thus it is plausible that Pro-B3 preferentially inhibits the p300-
dependent transcription of AR, rather than inhibiting transcription
mediated by Tip60.
In the present study, we provide evidence that Pro-B3, a HATi,
inhibits AR acetylation and suppresses AR-dependent prostate
cancer cell growth. Similar to HDAC inhibitors, the inhibition of
histone and non-histone protein acetylation can be exploited for
the development of new anticancer drugs. It seems contradictory
that both HATi and HDAC inhibitors have the same effect, since
these enzymes have opposing catalytic actions. However, the
molecular mechanisms of HATs and HDACs are complicated and
are still being explained, and the molecular basis of reversible
acetylation in tumorigenesis are not likely to be simple. Until
now, the deregulation of HATs has been associated with several
diseases, such as cardiac hypertrophy, asthma and cancer. In all of
these diseases, the cellular histone and non-histone proteins are
hyperacetylated. Therefore the selective and signalling-dependent
interference of target protein acetylation by HATi, like Pro-
B3, will enhance our understanding of acetylation events in
cellular function and may lead to a new class of therapeutic or
chemopreventive drugs.
Partial agonist activity of an antagonist is a potential
explanation for the clinical observation of hormone-withdrawn
syndrome [26−28]. Given that the functional dependence of
flutamide on HDAC corepressor has been demonstrated [21],
relative p300 HAT activity may be a critical point in the
efficacy of prostate cancer therapy. In fact, p300 expression
in high-grade tumours was shown to be higher compared with
low-grade tumours, and has prognostic values in predicting
long-term prostate cancer biochemical recurrence-free survival,
demonstrating that p300 expression in prostate cancer tissue may
be a useful marker for predicting progression [14]. In addition,
our data from immunohistochemistry analysis also confirmed the
pathological relevance of p300 expression with prostate cancer
progression. An important finding in the present study was that
Pro-B3 treatment potentiated the antagonist action of flutamide
via suppression of HAT. Indeed, several studies have demonstrated
that the overexpression of coactivators, including p300, results
in decreased antagonist activities of flutamide [14,21,29]. The
importance of balance between HDAC corepressors and HAT
coactivators has been emphasized in the control of AR protein
function [21]. The balance between HDAC and HAT protein
seems to determine the levels of histone and AR acetylation
and subsequent transcription. Consistent with this notion, our
results also demonstrate that the combined treatment of Pro-B3
and flutamide maximizes the efficacy of the antagonist activity.
Furthermore, as shown using the acetylation mutant GFP−AR,
the inhibitory effect of Pro-B3 on the growth and survival of
prostate cancer cells is mainly attributed to the acetylation of AR.
In this regard, we have reported the presence of anti-p300 activities
in natural compounds including Rosa rugosa [30] and allspice
extracts [31] which efficiently inhibit AR acetylation. In these
reports, both extracts were found to inhibit agonist-dependent AR
activation. Intriguingly, similar to Pro-B3, Rosa rugosa extracts
enhanced antagonist-dependent inhibition of AR transcription,
which resulted in reduced prostate cancer cell growth. Thus
developing drugs with increased ability to inhibit the AR−p300
interaction or AR acetylation is likely to improve the efficacy of
current anti-hormone therapies. In conclusion, the present study
raises the possibility that efficient interference of AR acetylation
by HATi could lead to a new class of antagonists for the treatment
of prostate cancer.
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Figure S1 Pro-B3 uncompetitively inhibits the p300 HAT activity
Lineweaver–Burk plot showing the effect of Pro-B3 on p300-mediated acetylation of core
histones. HAT assays were carried out with a fixed concentration of histones (8 pM) and
increasing concentration of [3H]acetyl CoA in the presence (50 and 100 μM) or absence of
Pro-B3. The results were plotted using Sigma Plot Version 10.0 (SYSTAT Software).
1 These authors contributed equally to the present study.
2 Correspondence may be addressed to either of these authors (email yhgeun@yuhs.ac or yna7315@cu.ac.kr).
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Figure S2 Western blot analysis for the wild-type and mutant AR–GFP expression plasmids
PC-3 cells were transfected with indicated GFP–AR (wt) or GFP–AR (mutant) expression plasmids. The cell lysates were analysed by Western blot using antibodies, as indicated.
Figure S3 Pro-B3 inhibits the expression of cell-cycle control genes
LNCaP cells were treated with either Pro-B3 or si-p300 in the presence or absence of R1881. The cell lysates were analysed by RT-PCR, as indicated.
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Figure S4 Pro-B3 efficiently promotes cellular apoptotic responses with antagonist
PC-3 cells were stained with FITC-conjugated with Annexin V. The cells were measured by flow cytometry. KQ, K630/632/633Q.
Figure S5 The effect of Pro-B3 treatment on the cellular localization of AR
LNCaP cells were transfected with GFP–AR (wt) in the presence or absence of R1881 and/or Pro-B3 as indicated and stained with DAPI (4′ ,6-diamidino-2-phenylindole). The stained cells were
observed by fluorescence microscopy.
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